Cancer drug pertuzumab tested for Long-Term use in extension trial
NCT ID NCT02320435
First seen Nov 15, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already taking it in a previous Roche study and still benefiting. About 154 participants will receive pertuzumab every 3 weeks, alone or with other treatments, until their disease worsens or side effects become unacceptable. Researchers will track how long the cancer stays controlled, overall survival, and any side effects, especially heart and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
A.O. Universitaria Pisana
Pisa, Tuscany, 56100, Italy
-
AUSL ? IRCCS Santa Maria Nuova
Reggio Emilia, Emilia-Romagna, 42100, Italy
-
Asan Medical Center
Seoul, 05505, South Korea
-
Asst Di Monza
Monza, Lombardy, 20052, Italy
-
Az. Osp. S. Orsola Malpighi
Bologna, Emilia-Romagna, 40138, Italy
-
Beijing Cancer Hospital
Beijing, 100142, China
-
Cancerologia de Queretaro
Querétaro City, Querétaro, 76090, Mexico
-
Centre Georges Francois Leclerc
Dijon, 21079, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Rene Huguenin
Saint-Cloud, 92210, France
-
Clinica Anglo Americana - Centro de Investigacion Oncologia CAA
Lima, L27, Peru
-
Clinica Internacional, Sede San Borja
Lima, Lima 41, Peru
-
Clinique Armoricaine Radiologie
Saint-Brieuc, 22015, France
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200120, China
-
Gifu University Hospital
Gifu, 501-1194, Japan
-
Harbin Medical University Cancer Hospital
Harbin, 150081, China
-
Hospital Amaral Carvalho
Jaú, São Paulo, 17210-080, Brazil
-
Hospital Metropolitano (Sede Lindora-Santa Ana)
San José, 10903, Costa Rica
-
Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud
Arequipa, 04001, Peru
-
Hospital Perola Byington
São Paulo, São Paulo, 01317-000, Brazil
-
Hospital Sírio-Libanês
São Paulo, São Paulo, 01308-050, Brazil
-
Hospital Universitari i Politecnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
-
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, 38320, Spain
-
Hospital da Luz
Lisbon, 1500-650, Portugal
-
Hospital de Basurto
Bilbao, Vizcaya, 48013, Spain
-
Hospital de Santa Maria
Lisbon, 1649-035, Portugal
-
Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus
Frankfurt am Main, 60389, Germany
-
ICO L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
IPO de Coimbra
Coimbra, 3000-075, Portugal
-
IPO do Porto
Porto, 4200-072, Portugal
-
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola
Meldola, Emilia-Romagna, 47014, Italy
-
Iem-Fucam
D.F., Mexico CITY (federal District), 04980, Mexico
-
Instituto Nacional de Cancer - INCa
Rio de Janeiro, 20560-120, Brazil
-
Instituto Nacional de Cancerologia
Distrito Federal, 14080, Mexico
-
Instituto de Oncologia de Sorocaba - CEPOS
Sorocaba, São Paulo, 18030-005, Brazil
-
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, 01246-000, Brazil
-
Irccs Ist. Tumori Giovanni Paolo Ii
Bari, Apulia, 70124, Italy
-
Irccs Istituto Europeo Di Oncologia (IEO)
Milan, Lombardy, 20141, Italy
-
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
Nanjing, 210029, China
-
Kursk Regional Clinical Oncology Dispensary
Kursk, 305035, Russia
-
Liaoning cancer Hospital & Institute
Shenyang, 110042, China
-
Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU
Dnipropetrovsk, 49102, Ukraine
-
National Cancer Center Hospital East
Chiba, 277-8577, Japan
-
Núcleo de Pesquisa São Camilo
São Paulo, São Paulo, 04014-002, Brazil
-
Onkologische Praxis Neumarkt (Dr. med. Ekkehart Ladda)
Neumarkt, 92318, Germany
-
Praxis für Ambulante Onkologie im Krankenhaus Jerusalem
Hamburg, 20357, Germany
-
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
Freiburg im Breisgau, 79110, Germany
-
SBI of Healthcare Samara Regional Clinical Oncology Dispensary
Samara, 443031, Russia
-
Saitama Cancer Center
Saitama, 362-0806, Japan
-
Samodzielny Publiczny Kliniczny Nr 1 W Lublinie
Lublin, 20-081, Poland
-
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90050-170, Brazil
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
State Oncology Regional Treatment-Diagnostic Center
Lviv, 79031, Ukraine
-
Studienzentrum UnterEms;Onkologische Schwerpunktpraxis Leer
Leer, 26789, Germany
-
The First Hospital of Jilin University
Changchun, 130021, China
-
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
-
West China Hospital, Sichuan University
Chengdu, 610041, China
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pertuzumab (Perjeta), alone or with trastuzumab or other anti-cancer drugs
What this could lead to
If successful, this study could confirm that long-term pertuzumab treatment is safe and effective for controlling certain solid tumors.
What could go wrong
This is an extension study with no control group, so results are limited. Side effects like heart problems or liver injury may occur, and not all patients will benefit.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.